Bloomberg Anywhere Remote Login Bloomberg Terminal Demo Request


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Bloomberg Customers

Markets & Finance

Goldman Sachs Ups Schering-Plough to In-Line

Goldman Sachs upgraded Schering-Plough (SGP) to in-line from underperform, citing factors such as the healthcare company's business making drugs to treat cholesterol.

Analyst James Kelly notes that cholesterol prescriptions were strong in early 2006; he raises his $3.4 billion 2006 cholesterol franchise revenue estimate to $3.8 billion. He says the risks in the cholesterol market (notably generic Zocor) highlight the importance of diversifying business risk through licensing or acquisitions of late stage products. He says shares are expensive at 20 times his 2008 earnings per share (EPS) estimate, but remain among the lowest price/sales in the sector. He raises his 46 cents 2006 EPS estimate to 50 cents and his 66 cents 2007 estimate to 69 cents.

blog comments powered by Disqus